Compare UFG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | LPCN |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 18.7M |
| IPO Year | 2024 | 2011 |
| Metric | UFG | LPCN |
|---|---|---|
| Price | $0.36 | $1.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 251.0K | ★ 1.5M |
| Earning Date | 09-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,976,677.00 |
| Revenue This Year | $26.00 | N/A |
| Revenue Next Year | N/A | $18.02 |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $1.59 |
| 52 Week High | $1.56 | $12.37 |
| Indicator | UFG | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 30.07 |
| Support Level | N/A | N/A |
| Resistance Level | $1.02 | $2.40 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 11.84 | 5.13 |
Uni-Fuels Holdings Ltd is a service provider of marine fuel solutions. It operates on an integrated business model, serving customers through two operating models: sales of marine fuels solutions and brokerage (i.e., acting as an intermediary between marine fuels suppliers and customers for a commission). The various marine fuel products offered by the company include very low sulfur fuel oil, high sulfur fuel oil, marine gas oil, and bio marine fuel. Its customers are mainly shipping companies and other fuel suppliers operating in market sectors such as bulk, tanker, offshore, container, general cargo, tug and barge, car carrier, cruise, yacht, and dredging. Geographically, the company derives maximum revenue from Singapore, and the rest from Malaysia, Hong Kong, China, and other regions.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.